Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: KW stock price vs RVMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Needs RVMD P/S.
Implied fair value · at KW's multiple
Needs KW P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: KW FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
12 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Kennedy-Wilson Holdings, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
2.91x
0.11x
Net debt / EBITDA
Leverage against operating earnings
16.00x
3.85x
Cash and equivalents
Liquid reserves on the balance sheet
$184.50M
$1.85B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CBRE GROUP, INC.
KW vs CBRE
JONES LANG LASALLE INC
KW vs JLL
SL GREEN REALTY CORP
KW vs SLG
BXP, Inc.
KW vs BXP
Four Corners Property Trust, Inc.
KW vs FCPT
Empire State Realty Trust, Inc.
KW vs ESRT
AMGEN INC
KW vs AMGN
BRISTOL MYERS SQUIBB CO
KW vs BMY
GILEAD SCIENCES, INC.
KW vs GILD
INCYTE CORP
KW vs INCY
VERTEX PHARMACEUTICALS INC / MA
KW vs VRTX
Moderna, Inc.
KW vs MRNA
$4.46B
$193.93M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
